Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
12.60
+1.08 (9.38%)
Feb 4, 2025, 4:00 PM EST - Market closed
Stoke Therapeutics Employees
Stoke Therapeutics had 110 employees as of December 31, 2023. The number of employees decreased by 7 or -5.98% compared to the previous year.
Employees
110
Change (1Y)
-7
Growth (1Y)
-5.98%
Revenue / Employee
$152,209
Profits / Employee
-$958,700
Market Cap
667.38M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
STOK News
- 27 days ago - Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
- 4 weeks ago - Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome - Business Wire
- 4 weeks ago - Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome - Business Wire
- 2 months ago - Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome - Business Wire
- 2 months ago - GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners - Business Wire
- 2 months ago - Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome - Business Wire
- 2 months ago - Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting - Business Wire
- 3 months ago - Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates - Business Wire